320 related articles for article (PubMed ID: 16041534)
21. Visuospatial working memory in Parkinson's disease.
Bradley VA; Welch JL; Dick DJ
J Neurol Neurosurg Psychiatry; 1989 Nov; 52(11):1228-35. PubMed ID: 2592967
[TBL] [Abstract][Full Text] [Related]
22. Rivastigmine in vascular dementia.
Vincent S; Lane R
Int Psychogeriatr; 2003; 15 Suppl 1():201-5. PubMed ID: 16191241
[TBL] [Abstract][Full Text] [Related]
23. Comparison of central and peripheral pharmacologic effects of biperiden and trihexyphenidyl in human volunteers.
Guthrie SK; Manzey L; Scott D; Giordani B; Tandon R
J Clin Psychopharmacol; 2000 Feb; 20(1):77-83. PubMed ID: 10653212
[TBL] [Abstract][Full Text] [Related]
24. Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind fMRI study.
Kumari V; Aasen I; ffytche D; Williams SC; Sharma T
Neuroimage; 2006 Jan; 29(2):545-56. PubMed ID: 16181792
[TBL] [Abstract][Full Text] [Related]
25. [Influence of attention on an auditory-verbal learning test in schizophrenic patients].
Huguelet P; Nicastro R; Zanello A
Encephale; 2002; 28(4):291-7. PubMed ID: 12232538
[TBL] [Abstract][Full Text] [Related]
26. Effect of rivastigmine on scopolamine-induced memory impairment in rats.
Bejar C; Wang RH; Weinstock M
Eur J Pharmacol; 1999 Nov; 383(3):231-40. PubMed ID: 10594314
[TBL] [Abstract][Full Text] [Related]
27. Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II--broader executive and non-executive domains.
Rhodes SM; Coghill DR; Matthews K
J Child Psychol Psychiatry; 2006 Nov; 47(11):1184-94. PubMed ID: 17076758
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of rivastigmine on executive function in patients with Parkinson's disease dementia.
Schmitt FA; Farlow MR; Meng X; Tekin S; Olin JT
CNS Neurosci Ther; 2010 Dec; 16(6):330-6. PubMed ID: 20950329
[TBL] [Abstract][Full Text] [Related]
29. Modelling Alzheimer-like cognitive deficits in rats using biperiden as putative cognition impairer.
Szczodry O; van der Staay FJ; Arndt SS
Behav Brain Res; 2014 Nov; 274():307-11. PubMed ID: 25160769
[TBL] [Abstract][Full Text] [Related]
30. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease.
Mehta MA; Sahakian BJ; McKenna PJ; Robbins TW
Psychopharmacology (Berl); 1999 Sep; 146(2):162-74. PubMed ID: 10525751
[TBL] [Abstract][Full Text] [Related]
31. Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior.
Goekoop R; Duschek EJ; Knol DL; Barkhof F; Netelenbos C; Scheltens P; Rombouts SA
Neuroimage; 2005 Mar; 25(1):63-75. PubMed ID: 15734344
[TBL] [Abstract][Full Text] [Related]
32. Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans.
Ellis JR; Ellis KA; Bartholomeusz CF; Harrison BJ; Wesnes KA; Erskine FF; Vitetta L; Nathan PJ
Int J Neuropsychopharmacol; 2006 Apr; 9(2):175-89. PubMed ID: 15877932
[TBL] [Abstract][Full Text] [Related]
33. The acetylcholinesterase inhibitor, ENA 713 (Exelon), attenuates the working memory impairment induced by scopolamine in an operant DNMTP task in rats.
Ballard TM; McAllister KH
Psychopharmacology (Berl); 1999 Sep; 146(1):10-8. PubMed ID: 10485959
[TBL] [Abstract][Full Text] [Related]
34. Rivastigmine for dementia associated with Parkinson's disease.
Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R
N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953
[TBL] [Abstract][Full Text] [Related]
35. Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse.
Chen Y; Shohami E; Constantini S; Weinstock M
J Neurotrauma; 1998 Apr; 15(4):231-7. PubMed ID: 9555969
[TBL] [Abstract][Full Text] [Related]
36. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
37. No interaction between rivastigmine and citalopram on memory and novelty processing in healthy human volunteers.
Heckman P; Blokland A; Sambeth A
J Psychopharmacol; 2019 Feb; 33(2):210-218. PubMed ID: 30226087
[TBL] [Abstract][Full Text] [Related]
38. Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes.
Mintzer MZ; Griffiths RR
Exp Clin Psychopharmacol; 2003 Feb; 11(1):56-72. PubMed ID: 12622344
[TBL] [Abstract][Full Text] [Related]
39. Double-blind crossover study of the cognitive effects of lorazepam in healthy apolipoprotein E (APOE)-epsilon4 carriers.
Stonnington CM; Snyder PJ; Hentz JG; Reiman EM; Caselli RJ
J Clin Psychiatry; 2009 Oct; 70(10):1379-84. PubMed ID: 19573495
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of rivastigmine against 3-nitropropionic acid-induced Huntington's disease like symptoms: possible behavioural, biochemical and cellular alterations.
Kumar P; Kumar A
Eur J Pharmacol; 2009 Aug; 615(1-3):91-101. PubMed ID: 19445928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
